The content on this website has been developed solely by Celgene.
NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY
(NCCN GUIDELINES®) RECOMMENDATIONS10*
Advanced or Metastatic Squamous Cell NSCLC
+ carboplatin + pembrolizumab
Category 1 Preferred for PD-L1 1%-49%a
- *For additional considerations and treatment options, see NCCN.org.
- a Category 1: Based on high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
- b If progression on PD-1/PD-L1 inhibitor, switching to another PD-1/PD-L1 inhibitor is not routinely recommended.
- c PD-L1 ≥1% and EGFR, ALK negative or unknown, treatment option for patients with no contraindications to the addition of pembrolizumab or atezolizumab. Contraindications for treatment with PD-1/PD-L1 inhibitors may include active or previously documented autoimmune disease and/or current use of immunosuppressive agents or presence of an oncogene, which would predict lack of benefit.